Literature DB >> 16621425

Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.

F Raspagliesi1, S Kusamura, J C Campos Torres, G A de Souza, A Ditto, F Zanaboni, R Younan, D Baratti, L Mariani, B Laterza, M Deraco.   

Abstract

AIMS: We report the effects of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of advanced/recurrent epithelial ovarian cancer (EOC) on survival, morbidity and mortality. PATIENTS: Forty EOC patients were studied. Median age was 52.5 years (range: 30-68) and median follow-up 26.1 months (range: 0.3-117.6). Most patients presented advanced disease (stage III/IV). Previous systemic chemotherapy included cisplatin-based, taxol-based or taxol/platinum containing regimens.
RESULTS: After the CRS, 33 patients presented no macroscopic residual disease. Five-year overall survival was 15%; the mean overall and progression-free survivals were 41.4 and 23.9 months, respectively. The morbidity, toxicity and mortality rates were 5%, 15% and 0%, respectively.
CONCLUSION: Our results suggest that CRS + IPHP merits further evaluation by a formal prospective trial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621425     DOI: 10.1016/j.ejso.2006.03.011

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  17 in total

Review 1.  Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Authors:  Ramez N Eskander; James Cripe; Robert E Bristow
Journal:  Curr Treat Options Oncol       Date:  2014-03

Review 2.  The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.

Authors:  E Saladino; F Fleres; S Irato; C Famulari; A Macrì
Journal:  Updates Surg       Date:  2013-08-27

Review 3.  Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Authors:  Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-23       Impact factor: 4.553

4.  Intraperitoneal hyperthermic chemotherapy: which drugs?

Authors:  Jacopo Giuliani
Journal:  J Gastrointest Cancer       Date:  2014-03

Review 5.  Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.

Authors:  Federico Coccolini; Paola Fugazzola; Giulia Montori; Luca Ansaloni; Massimo Chiarugi
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 6.  [Surgical treatment of peritoneal metastases from gynecological primary tumors].

Authors:  P Horvath; A Königsrainer
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.

Authors:  Ingmar Königsrainer; Philipp Horvath; Florian Struller; Eva Maria Grischke; Diethelm Wallwiener; Alfred Königsrainer; Stefan Beckert
Journal:  Langenbecks Arch Surg       Date:  2014-05-11       Impact factor: 3.445

Review 8.  The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.

Authors:  Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-16

Review 9.  Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes.

Authors:  Harveshp Mogal; Konstantinos Chouliaras; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 10.  Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.

Authors:  F C Muñoz-Casares; S Rufián; M J Rubio; E Lizárraga; C Díaz-Iglesias; E Aranda; R Ciria; J Muntané; P Barrios; J Torres-Melero; S González-Moreno; L González-Bayón; B Camps; P Bretcha; J Farré; G Ortega-Pérez; A Gómez-Portilla
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.